BMS-351 is a potent and selective, nonsteroidal CYP17A1 lyase inhibitor with robust selectivity over steroidogenic CYPs 21A2 and 11B1. BMS-351 emerges as an outstanding preclinical candidate to treat CRPC and is likely to minimize the side effects of current therapies due to its exceptional selectivity. BMS-351 is potentially useful for the Treatment of Prostate Cancer.
Molecular Weight:
291.27
CAS Number:
[1370001-71-0]
Formula:
C15H12F3N3
Target:
Cytochromes P450|||Others
T70847
* VAT and and shipping costs not included. Errors and price changes excepted